Robert Bona, MD
Professor of Medicine (Hematology)Cards
About
Research
Publications
2024
Preventing Long-Term Neurologic Disability in Hemophilia (A): Cost-Effectiveness of Emicizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia (A)
Glaeser-Khan S, Richmond R, Ito S, Bona R, Krumholz H, Cuker A, Goshua G. Preventing Long-Term Neurologic Disability in Hemophilia (A): Cost-Effectiveness of Emicizumab Prophylaxis for the Prevention of Intracranial Hemorrhage in Infants with Severe Hemophilia (A). Blood 2024, 144: 157-157. DOI: 10.1182/blood-2024-203690.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioStandard-of-careStandard half-lifeEmicizumab prophylaxisSevere hemophilia AIntracranial hemorrhageIntracranial hemorrhage incidenceSevere HAHemophilia AProbabilistic sensitivity analysesYears of agePrevention of intracranial hemorrhageNeurological disabilityPrevent intracranial hemorrhageIntracranial hemorrhage eventsIntracranial hemorrhage riskPhase III studyBase-casePersistent neurological disabilityAged 1 monthFactor VIII replacementStandard-of-care armUS societal perspectiveInfants aged 0Aged 0Characterizing an Underdiagnosed Condition: Hemophilia in Females
Restrepo V, Prozora S, Louizos E, Van Doren L, Bona R. Characterizing an Underdiagnosed Condition: Hemophilia in Females. Blood 2024, 144: 2584-2584. DOI: 10.1182/blood-2024-210735.Peer-Reviewed Original ResearchPost-partum hemorrhageHeavy menstrual bleedingIron deficiency anemiaLow factor levelsClotting factor levelsHemophilia treatment centersHaemophilia carriersBlood transfusionHemophilia RegistryFactor deficiencyFactor levelsRates of heavy menstrual bleedingFrequency of blood transfusionLife-threatening bleedingFactor replacement therapyManagement of HCAnti-fibrinolytic agentDiagnosis of HCAge of diagnosisHemophilia B carriersYale-New Haven HospitalHealthcare disparitiesNormal factor VIIIHemophilia A carriersFactor activityPhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityCost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States
Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood 2024, 143: 2332-2335. PMID: 38635764, DOI: 10.1182/blood.2024024209.Peer-Reviewed Original ResearchJoint bleeds in mild hemophilia: Prevalence and clinical characteristics
Chiari J, Prozora S, Feinn R, Louizos E, Gallagher P, Bona R. Joint bleeds in mild hemophilia: Prevalence and clinical characteristics. Haemophilia 2024, 30: 331-335. PMID: 38240020, DOI: 10.1111/hae.14939.Peer-Reviewed Original ResearchMild haemophiliaJoint bleedsJoint range of motionHepatitis CRange of motionMild diseaseHistory of joint bleedsInstitutional review board approvalJoint rangeRetrospective chart reviewHemophilia treatment centersReview board approvalJoint healthHistory of traumaDisease burdenMedical recordsChart reviewClinical characteristicsMitigate disease burdenRisk factorsBoard approvalBleedingTraumatic bleedingAverage ageHemophilic arthropathy
2023
Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groupsCharacterizing Outpatient Classical Hematology Referrals at an Academic Healthcare System
Chang E, Kress A, Ackermann F, Fradkin M, Halene S, Herbert E, Shomsky L, Sudhakar L, Lee A, Bona R. Characterizing Outpatient Classical Hematology Referrals at an Academic Healthcare System. Blood 2023, 142: 7196. DOI: 10.1182/blood-2023-186065.Peer-Reviewed Original ResearchIron deficiency anemiaAdvanced practice providersManual chart reviewChart reviewDeficiency anemiaHematology referralCommon diagnosisNew patientsAnemia groupDiagnosis levelClinical sitesIron deficiency groupAcademic healthcare systemHealthcare systemICD-10 codesNew patient encountersICD diagnosis codesSubstantial patient populationLevel 1 casesLevel 1Available cliniciansThrombosis groupAdditional patientsLevel 3New referralsCost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease
Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease. Blood 2023, 142: 3698. DOI: 10.1182/blood-2023-188018.Peer-Reviewed Original ResearchSevere von Willebrand diseaseLong-term prophylaxisIncremental net monetary benefitVon Willebrand diseasePlasma-derived von Willebrand factorIncremental cost-effectiveness ratioNet monetary benefitVon Willebrand factorProbabilistic sensitivity analysesDeterministic sensitivity analysesSevere haemophiliaWillebrand factorRecombinant von Willebrand factorWillebrand diseasePhase 3 clinical trialsHealth resource utilizationFactor replacement therapyFrequency of infusionsSubset of patientsCost of prophylaxisType 3 von Willebrand diseaseFactor replacement productsSimilar significant improvementsSevere phenotypeNon-significant reductionEquitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States
Ito S, Potnis K, Allen C, Richmond R, Waldron C, Viswanathan G, Bona R, Goshua G. Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States. Blood 2023, 142: 492. DOI: 10.1182/blood-2023-190420.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia A.Quality-adjusted life expectancySevere haemophilia AHemophilia AFactor VIIIDistributional cost-effectiveness analysisHemophilia A.Chronic arthropathyOpen-label multicenter studyCoagulation factor replacementLifelong prophylactic treatmentCare of patientsCost-effectiveness ratioUSD/QALYProbabilistic sensitivity analysesCost-effectiveness analysisPackage insert informationDeterministic sensitivity analysesWeekly prophylaxisPrimary outcomeSecondary outcomesWeekly dosingFactor replacementIntracranial hemorrhageCost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.Peer-Reviewed Original Research
Clinical Care
Overview
Robert Bona, MD, is a Yale Cancer Center hematologist. He cares for individuals with blood disorders, including those with excessive bleeding or clotting, those with low red blood cell (anemia), low platelet, or white cell counts, and those with disorders of iron metabolism. He is the director of the Classical Hematology Program at Smilow Cancer Hospital (which treats non-cancer-related blood disorders) and medical director of the Yale Hemophilia Treatment Center.
Dr. Bona says he has been interested in blood disorders since medical school, where he studied with some of the top experts in the field. “I’ve always been interested in looking at blood cells under the microscope and studying blood coagulation and clotting,” he says.
As a Yale Medicine clinician, he often works with teams that include advanced practitioners, nurses, and other specialized physicians from medicine, laboratory medicine, and transfusion medicine, as well as medical providers from related areas such as surgery and radiology.
For those individuals asking for advice or care, he suggests they come to their visit with a sense of what they want to talk about. “Come with an agenda. It might be to discuss your diagnosis, treatment for your disease, or other diagnostic possibilities if the diagnosis has not yet been made,” he says. If you are coming from a medical center with a different medical record system, making your complete medical record available is important to have an optimal visit. It also helps, if you wish, to bring a family member or friend to talk to us about complex medical issues.”
In addition to his clinical work, Dr. Bona is a professor of medicine (hematology) at Yale School of Medicine. He has strong interests in medical education and research interests in new treatments for people with bleeding or clotting disorders. “The education and training of our next generation of physicians and medical educators is very important to me,” he says.
Prior to coming to Yale, Dr. Bona was a founding faculty member of the Frank H. Netter MD School of Medicine at Quinnipiac University. Prior to that, he worked in the Hematology-Oncology division at the University of Connecticut.
Clinical Specialties
Fact Sheets
Anemia
Learn More on Yale MedicineCerebral Venous Sinus Thrombosis (CVST)
Learn More on Yale MedicineBleeding Disorders
Learn More on Yale MedicineDeep Vein Thrombosis
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2015
- Original Certification Date
- 1986
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1985
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1983
Yale Medicine News
News & Links
News
- December 05, 2024
Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder
- April 30, 2024Source: Mint
Thrombosis Thrombocytopenia Syndrome: Symptoms of TTS. Rare Side-Effect of AstraZeneca Covid Vaccine Explained
- March 25, 2024
Yale’s Post ASH Review
- February 15, 2024
Educational Exchange Brings Ugandan Hematologist Dr. Christine Sekaggya-Wiltshire to Yale School of Medicine